Open AccessThis article is
- freely available
Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
Krankenanstalt Rudolfstiftung, Second Medical Department, Juchgasse 25, Wien A-1030, Austria
Danube University Krems, Doktor-Karl-Dorrek-Straße 30, Krems A-3500, Austria
* Author to whom correspondence should be addressed.
Received: 26 December 2011; in revised form: 1 February 2012 / Accepted: 1 February 2012 / Published: 3 February 2012
Abstract: Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are still unclear, like laboratory monitoring, use in elderly patients, drug- and food-interactions and use in patients with renal insufficiency. Additionally, there is no antidote for dabigatran. Thus, aim of the present review is to give an overview of concerns and unresolved issues concerning dabigatran.
Keywords: atrial fibrillation; dabigatran; anticoagulation
Citations to this Article
Cite This Article
MDPI and ACS Style
Stöllberger, C.; Finsterer, J. Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation. Pharmaceuticals 2012, 5, 155-168.
Stöllberger C, Finsterer J. Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation. Pharmaceuticals. 2012; 5(2):155-168.
Stöllberger, Claudia; Finsterer, Josef. 2012. "Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation." Pharmaceuticals 5, no. 2: 155-168.